Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022

化学療法誘発性好中球減少症治療薬の世界市場2018-2022

◆タイトル:Global Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022
◆商品コード:IRTNTR22916
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年5月15日
◆ページ数:102
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Healthcare and Life Sciences
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、化学療法誘発性好中球減少症治療薬の世界市場について調査・分析し、市場概要、市場環境、化学療法誘発性好中球減少症治療薬市場規模、処置別(G-CSF療法、顆粒球輸血、抗生物質治療、脾臓摘出術)分析、市場動向、競争環境、主要地域別市場規模(アメリカ、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・化学療法誘発性好中球減少症治療薬の世界市場概要
・化学療法誘発性好中球減少症治療薬の世界市場環境
・化学療法誘発性好中球減少症治療薬の世界市場動向
・化学療法誘発性好中球減少症治療薬の世界市場規模
・化学療法誘発性好中球減少症治療薬の世界市場:業界構造分析
・化学療法誘発性好中球減少症治療薬の世界市場:処置別(G-CSF療法、顆粒球輸血、抗生物質治療、脾臓摘出術)
・化学療法誘発性好中球減少症治療薬の世界市場:地域別市場規模・分析
・化学療法誘発性好中球減少症治療薬のアメリカ市場規模・予測
・化学療法誘発性好中球減少症治療薬のヨーロッパ市場規模・予測
・化学療法誘発性好中球減少症治療薬のアジア市場規模・予測
・化学療法誘発性好中球減少症治療薬の主要国分析
・化学療法誘発性好中球減少症治療薬の世界市場:意思決定フレームワーク
・化学療法誘発性好中球減少症治療薬の世界市場:成長要因、課題
・化学療法誘発性好中球減少症治療薬の世界市場:競争環境
・化学療法誘発性好中球減少症治療薬の世界市場:関連企業情報(ベンダー分析)

About Chemotherapy-induced Neutropenia Therapeutics

Neutrophils are immunity-inducing white blood cells. Reduction in its number causes neutropenia. Chemotherapy-induced neutropenia occurring during treatment increases patient’s risk of infection and disrupts cancer treatment.

Technavio’s analysts forecast the Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow at a CAGR of 5.52% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global chemotherapy-induced neutropenia therapeutics market. To calculate the market size, the report considers the revenue generated from the adoption of CIN treatment.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, global chemotherapy-induced neutropenia therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Amgen
• Intas Pharmaceuticals
• Novartis
• Partner Therapeutics
• Teva Pharmaceuticals Industries

Market driver
• Rapid development in molecular oncology
• For a full, detailed list, view our report

Market challenge
• Lack of accessibility and affordability of cancer therapy in developing countries
• For a full, detailed list, view our report

Market trend
• Technological advancements
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PROCEDURE
• Segmentation by procedure
• Comparison by procedure
• G-CSF therapy – Market size and forecast 2017-2022
• Granulocyte transfusion – Market size and forecast 2017-2022
• Antibiotic therapy – Market size and forecast 2017-2022
• Splenectomy – Market size and forecast 2017-2022
• Market opportunity by procedure
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Increase in global awareness about cancer treatments
• Technological advancements
• Strategic alliances
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• Intas Pharmaceuticals
• Novartis
• Partner Therapeutics
• Teva Pharmaceuticals Industries
PART 15: APPENDIX
• List of abbreviations

• Exhibit 01: Related market
• Exhibit 02: Market characteristics
• Exhibit 03: Market segments
• Exhibit 04: Market definition – Inclusions and exclusions checklist
• Exhibit 05: Market size 2017
• Exhibit 06: Validation techniques employed for market sizing 2017
• Exhibit 07: Global – Market size and forecast 2017-2022 ($ mn)
• Exhibit 08: Global – Year-over-year growth 2018-2022 (%)
• Exhibit 09: Five forces analysis 2017
• Exhibit 10: Five forces analysis 2022
• Exhibit 11: Bargaining power of buyers
• Exhibit 12: Bargaining power of suppliers
• Exhibit 13: Threat of new entrants
• Exhibit 14: Threat of substitutes
• Exhibit 15: Threat of rivalry
• Exhibit 16: Market condition – Five forces 2017
• Exhibit 17: Procedure – Market share 2017-2022 (%)
• Exhibit 18: Comparison by procedure
• Exhibit 19: G-CSF therapy – Market size and forecast 2017-2022 ($ mn)
• Exhibit 20: G-CSF therapy – Year-over-year growth 2018-2022 (%)
• Exhibit 21: Granulocyte transfusion – Market size and forecast 2017-2022 ($ mn)
• Exhibit 22: Granulocyte transfusion – Year-over-year growth 2018-2022 (%)
• Exhibit 23: Antibiotic therapy – Market size and forecast 2017-2022 ($ mn)
• Exhibit 24: Antibiotic therapy – Year-over-year growth 2018-2022 (%)
• Exhibit 25: Splenectomy – Market size and forecast 2017-2022 ($ mn)
• Exhibit 26: Splenectomy – Year-over-year growth 2018-2022 (%)
• Exhibit 27: Market opportunity by procedure
• Exhibit 28: Customer landscape
• Exhibit 29: Global – Market share by geography 2017-2022 (%)
• Exhibit 30: Regional comparison
• Exhibit 31: Americas – Market size and forecast 2017-2022 ($ mn)
• Exhibit 32: Americas – Year-over-year growth 2018-2022 (%)
• Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn)
• Exhibit 34: EMEA – Year-over-year growth 2018-2022 (%)
• Exhibit 35: APAC – Market size and forecast 2017-2022 ($ mn)
• Exhibit 36: APAC – Year-over-year growth 2018-2022 (%)
• Exhibit 37: Key leading countries
• Exhibit 38: Market opportunity
• Exhibit 39: R&D funding for cancer for FY2013 to FY2016 ($ millions)
• Exhibit 40: Vendor landscape
• Exhibit 41: Landscape disruption
• Exhibit 42: Vendor classification
• Exhibit 43: Market positioning of vendors
• Exhibit 44: Amgen overview
• Exhibit 45: Amgen – Business segments
• Exhibit 46: Amgen – Organizational developments
• Exhibit 47: Amgen – Geographic focus
• Exhibit 48: Amgen – Key offerings
• Exhibit 49: Intas Pharmaceuticals overview
• Exhibit 50: Intas Pharmaceuticals – Business segments
• Exhibit 51: Intas Pharmaceuticals – Organizational developments
• Exhibit 52: Intas Pharmaceuticals – Geographic focus
• Exhibit 53: Intas Pharmaceuticals – Segment focus
• Exhibit 54: Intas Pharmaceuticals – Key offerings
• Exhibit 55: Novartis overview
• Exhibit 56: Novartis – Business segments
• Exhibit 57: Novartis – Organizational developments
• Exhibit 58: Novartis – Geographic focus
• Exhibit 59: Novartis – Segment focus
• Exhibit 60: Novartis – Key offerings
• Exhibit 61: Partner Therapeutics overview
• Exhibit 62: Partner Therapeutics – Business segments
• Exhibit 63: Partner Therapeutics – Organizational developments
• Exhibit 64: Partner Therapeutics – Geographic focus
• Exhibit 65: Partner Therapeutics – Key offerings
• Exhibit 66: Teva Pharmaceuticals Industries overview
• Exhibit 67: Teva Pharmaceuticals Industries – Business segments
• Exhibit 68: Teva Pharmaceuticals Industries – Organizational developments
• Exhibit 69: Teva Pharmaceuticals Industries – Geographic focus
• Exhibit 70: Teva Pharmaceuticals Industries – Segment focus
• Exhibit 71: Teva Pharmaceuticals Industries – Key offerings



【掲載企業】

Amgen
Intas Pharmaceuticals
Novartis
Partner Therapeutics
Teva Pharmaceuticals Industries

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[化学療法誘発性好中球減少症治療薬の世界市場2018-2022]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆